Lymphoma, B-Cell Clinical Trials

None

Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …

UPCC 03419: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma

This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)

UPCC 54417: Phase I/II study of pembrolizumab in patients with relapsed or refractory extranodal NK/T cell lymphoma (ENKTL) nasal type and EBV-associated diffuse large B cell lymphomas (EBV-DLBCL)

The purpose of this study is to determine the safety and tolerability of pembrolizumab in people with lymphoma whose lymphoma relapsed or did not respond after receiving at least one prior treatment for lymphoma. This study will also determine how well patients with lymphoma respond to pembrolizumab.

UPCC 34418: A phase Ib multicenter study to determine the safety and tolerability of tisagenlecleucel in combination with ibrutinib in adult patients with relapsed and/or refractory diffuse large B-cell lymphoma

The purpose of the study is to find out if an engineered T-cell therapy (tisagenlecleucel) in combination with ibrutinib is safe and tolerable for people with relapsed and/or refractory diffuse large B-cell lymphoma.

UPCC 38417: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

TBD